ERBITUX for Neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 7 adverse event reports in the FDA FAERS database where ERBITUX was used for Neoplasm malignant.
Most Reported Side Effects for ERBITUX
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Rash | 114 | 17.1% | 1 | 3 |
| Infusion related reaction | 44 | 6.6% | 1 | 6 |
| Malaise | 37 | 5.6% | 0 | 1 |
| Speech disorder | 32 | 4.8% | 1 | 0 |
| Dry skin | 31 | 4.7% | 0 | 0 |
| Diarrhoea | 25 | 3.8% | 1 | 6 |
| Pruritus | 24 | 3.6% | 0 | 2 |
| Death | 23 | 3.5% | 23 | 4 |
| Adverse event | 21 | 3.2% | 1 | 9 |
| Malignant neoplasm progression | 20 | 3.0% | 10 | 4 |
| Dyspnoea | 19 | 2.9% | 1 | 6 |
| Acne | 18 | 2.7% | 1 | 1 |
| Hypomagnesaemia | 18 | 2.7% | 0 | 1 |
| Skin disorder | 18 | 2.7% | 0 | 0 |
| Weight decreased | 18 | 2.7% | 2 | 3 |
Other Indications for ERBITUX
Head and neck cancer (70)
Colon cancer (56)
Colorectal cancer (39)
Colorectal cancer metastatic (28)
Colon cancer metastatic (17)
Squamous cell carcinoma (12)
Throat cancer (12)
Rectal cancer (7)
Lung neoplasm malignant (6)
Product used for unknown indication (6)
Other Drugs Used for Neoplasm malignant
PALBOCICLIB (1,996)
CAPECITABINE (1,493)
PEMBROLIZUMAB (1,135)
PACLITAXEL (984)
CARBOPLATIN (977)
NIVOLUMAB (947)
OXALIPLATIN (823)
PAZOPANIB (716)
CYCLOPHOSPHAMIDE (685)
FLUOROURACIL (676)